Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights – SRPT

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from June 22, 2023, to June 24, 2025, Sarepta Therapeutics made materially false and misleading statements regarding ELEVIDYS, a gene therapy for Duchenne muscular dystrophy. Specific allegations include: - Significant safety risks associated with ELEVIDYS were not disclosed [3]. - Trial protocols failed to identify severe side effects [3]. - Adverse events from ELEVIDYS treatment could lead to halting recruitment and dosing in trials, attracting regulatory scrutiny [3]. - The misleading statements resulted in a lack of reasonable basis for the company's positive outlook on the therapy [3]. Class Action Details - Shareholders who purchased shares of SRPT during the specified class period are encouraged to register for the class action. The deadline for seeking lead plaintiff status is August 25, 2025 [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud. The firm aims to ensure companies engage in responsible business practices [5].